Wang Y., Wang H., Chai K., Guo S., Zhai Y., Shi R., Zhang F., Huang J., Jin Z., Gao Y., Tao X., Yang S., Li J., Zhou J., Qiao C., Stalin A., Wu J. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine. 2024;123:155242.
Rationale
Lentinan — a shiitake β-(1→3)-glucan — is the only mushroom polysaccharide registered as an injectable oncology adjunct in Japan and China, alongside PSK. This meta-analysis asks the straight clinical question: does it add benefit over chemotherapy alone in gastric cancer?
Methods
Six databases searched to March 2023; RCTs of lentinan + chemo in gastric cancer; RevMan 5.3 with risk-of-bias assessment, trial sequential analysis and GRADE certainty grading. 31 RCTs, n=2,729.
Results
- Efficacy: RR 1.48 (1.36–1.61) for lentinan+chemo.
- Quality of life: RR 1.32 (1.20–1.45).
- Immune indices: ↑ CD3+, CD4+, CD4+/CD8+ ratio, NK cells.
- Chemo toxicity ↓: less leukopenia, GI reactions, thrombocytopenia.
- No serious adverse events; TSA: sufficient data; GRADE: high/moderate.
Conclusions
Injectable lentinan added to chemotherapy improved efficacy, quality of life and tolerability in gastric cancer without serious adverse effects; the authors call for further high-quality RCTs.
Worth noting
Two caveats carry the weight. First, this is an injectable pharmaceutical, not a supplement — the findings don't transfer to shiitake capsules. Second, essentially all 31 RCTs are Chinese; TCM-injection trials carry known risks of publication and methodological bias, so "GRADE high/moderate" describes certainty within that evidence base, not applicability to Western oncology. Still, the broader fact stands: lentinan is the one mushroom β-glucan that crossed from supplement niche into a licensed oncology adjunct — alongside Japanese PSK.